ArticleInternational journal of nanomedicine2013
Cytoprotective and enhanced anti-inflammatory activities of liposomal piroxicam formulation in lipopolysaccharide-stimulated RAW 264.7 macrophages.
Article in International journal of nanomedicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 37 citations in OpenAlex.
- Network Pharmacology of the Phytochemical Content of Sunflower Seed (Plants (Basel, Switzerland) · 2026Article
- Liposome-Encapsulated Melatonin Mitigates Amoxicillin-Induced Neurotoxicity in a Zebrafish.Journal of cellular and molecular medicine · 2025Article
- Ole-Oxy, a Semi-Synthetic Analog of Oleuropein, Ameliorates Acute Skin and Colon Inflammation in Mice.Antioxidants (Basel, Switzerland) · 2024Article
- The characteristics and biological activity enhancements of melatonin encapsulations for skin care product applications.International journal of pharmaceutics: X · 2023Article
- The Anti-Arthritic Activity of Diclofenac Lipid-Core Nanocapsules: Stereological Analysis Showing More Protection of Deep Joint Components.Molecules (Basel, Switzerland) · 2023Article
- Phytosome Supplements for DeliveringFoods (Basel, Switzerland) · 2023Article
- Development of a Sericin Hydrogel to Deliver Anthocyanins from Purple Waxy Corn Cob (Pharmaceutics · 2022Article
- Exploiting the Anti-Inflammatory Potential of WhiteAntioxidants (Basel, Switzerland) · 2021Article
- Modulation of Inflammatory Mediators by Polymeric Nanoparticles Loaded with Anti-Inflammatory Drugs.Pharmaceutics · 2021Article
- Update on Nanoparticle-Based Drug Delivery System for Anti-inflammatory Treatment.Frontiers in bioengineering and biotechnology · 2021Review
- Liposomal glutathione as a promising candidate for immunological rheumatoid arthritis therapy.Heliyon · 2019Article
- Antifungal-demelanizing properties and RAW264.7 macrophages stimulation of glucan sulfate from the mycelium of the mushroomFood science and biotechnology · 2017Article
- Therapeutic effects of lornoxicam-loaded nanomicellar formula in experimental models of rheumatoid arthritis.International journal of nanomedicine · 2017Article
- Nanomedicine delivers promising treatments for rheumatoid arthritis.Nanomedicine (London, England) · 2015Review
- Mefenamic Acid induced nephrotoxicity: an animal model.Advanced pharmaceutical bulletin · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiposomal drug delivery systems, a promising lipid-based nanoparticle technology, have been known to play significant roles in improving the safety and efficacy of an encapsulated drug.
methodsLiposomes, prepared using an optimized proliposome method, were used in the present work to encapsulate piroxicam, a widely prescribed nonsteroidal anti-inflammatory drug. The cytotoxic effects as well as the in vitro efficacy in regulation of inflammatory responses by free-form piroxicam and liposome-encapsulated piroxicam were evaluated using a lipopolysaccharide-sensitive macrophage cell line, RAW 264.7.
resultsCells treated with liposome-encapsulated piroxicam demonstrated higher cell viabilities than those treated with free-form piroxicam. In addition, the liposomal piroxicam formulation resulted in statistically stronger inhibition of pro-inflammatory mediators (ie, nitric oxide, tumor necrosis factor-α, interleukin-1β, and prostaglandin E2) than piroxicam at an equivalent dose. The liposome-encapsulated piroxicam also caused statistically significant production of interleukin-10, an anti-inflammatory cytokine.
conclusionThis study affirms the potential of a liposomal piroxicam formulation in reducing cytotoxicity and enhancing anti-inflammatory responses in vitro.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.